Can Samsara Hill Resort help Leisure Hotels Group turn Mussoorie pressure into premium pricing power?
Read More Pharma Industry News Biogen (BIIB) buys felzartamab rights in China from TJ Biopharma for up to $850m, completing global ownership Biogen pays $100M upfront for felzartamab's China rights from TJ Biopharma, completing global ownership of the CD38 antibody with up to $850M at stake. Read the full analysis. byVenkateshApril 21, 2026